ES2219028T3 - Uso de bisfosfonatos para el tratamiento de restenosis vascular. - Google Patents

Uso de bisfosfonatos para el tratamiento de restenosis vascular.

Info

Publication number
ES2219028T3
ES2219028T3 ES99929687T ES99929687T ES2219028T3 ES 2219028 T3 ES2219028 T3 ES 2219028T3 ES 99929687 T ES99929687 T ES 99929687T ES 99929687 T ES99929687 T ES 99929687T ES 2219028 T3 ES2219028 T3 ES 2219028T3
Authority
ES
Spain
Prior art keywords
treatment
bisphosphonates
vascular restenosis
restenosis
vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99929687T
Other languages
English (en)
Inventor
Gershon Golomb
Haim Daneberg
Dr Jukka Minkkinen
Dr Ilia Fishbein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Hadasit Medical Research Services and Development Co
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Hadasit Medical Research Services and Development Co
Application granted granted Critical
Publication of ES2219028T3 publication Critical patent/ES2219028T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Saccharide Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso de un ingrediente activo que es bisfosfonato (BP) en partículas, o un complejo en partículas o una sal de BP, o polímero en partículas de BP, que está en una forma de partículas micronizadas que tienen un diámetro en el intervalo de 0, 01- 10 my-m, para la preparación de una composición farmacéutica destinada a la prevención o tratamiento de restenosis vascular.
ES99929687T 1998-07-14 1999-07-14 Uso de bisfosfonatos para el tratamiento de restenosis vascular. Expired - Lifetime ES2219028T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL12533698A IL125336A0 (en) 1998-07-14 1998-07-14 Compositions for inhibition and treatment of restinosis

Publications (1)

Publication Number Publication Date
ES2219028T3 true ES2219028T3 (es) 2004-11-16

Family

ID=11071743

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04006854T Expired - Lifetime ES2347553T3 (es) 1998-07-14 1999-07-14 Uso de bisfosfonatos en el tratamiento de la reestenosis vascular.
ES99929687T Expired - Lifetime ES2219028T3 (es) 1998-07-14 1999-07-14 Uso de bisfosfonatos para el tratamiento de restenosis vascular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES04006854T Expired - Lifetime ES2347553T3 (es) 1998-07-14 1999-07-14 Uso de bisfosfonatos en el tratamiento de la reestenosis vascular.

Country Status (17)

Country Link
US (1) US6719998B1 (es)
EP (2) EP1468691B1 (es)
JP (4) JP4663116B2 (es)
KR (1) KR20010074711A (es)
CN (1) CN1321090A (es)
AT (2) ATE262338T1 (es)
AU (1) AU758882B2 (es)
BR (1) BR9912066A (es)
CA (1) CA2337175C (es)
DE (2) DE69915834T2 (es)
EE (1) EE200100025A (es)
ES (2) ES2347553T3 (es)
IL (3) IL125336A0 (es)
NO (1) NO20010224L (es)
PL (1) PL345782A1 (es)
SK (1) SK472001A3 (es)
WO (1) WO2000003677A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
DK1178810T3 (da) * 1999-05-21 2005-07-11 Novartis Ag Anvendelse af bisphosphonsyrer til behandling af angiogenese
WO2001049295A1 (en) * 2000-01-04 2001-07-12 The Regents Of The University Of California Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification
CN100469394C (zh) * 2001-02-16 2009-03-18 艾伯特实验室血管有限公司 具有fk506的植入体
US6656506B1 (en) * 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
BR0315383A (pt) * 2002-10-15 2005-08-23 Novartis Ag Biofosfofatos para o tratamento de aterosclerose e dispositivos compreendendo os mesmos
US8034361B2 (en) * 2002-11-12 2011-10-11 Advanced Cardiovascular Systems, Inc. Stent coatings incorporating nanoparticles
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
JP4621202B2 (ja) * 2003-06-27 2011-01-26 バイオレスト リミテッド 急性冠症候群を治療する方法
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20050153937A1 (en) * 2003-11-07 2005-07-14 Gershon Golomb Desensitization of compliment activation using monocyte/macrophage inhibitory compounds
CN100364544C (zh) * 2004-07-21 2008-01-30 上海第二医科大学附属瑞金医院 一种携带二氯亚甲基二膦酸的明胶微粒及制备方法
US8012949B2 (en) 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7687482B2 (en) 2006-03-17 2010-03-30 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
EP1802641B8 (en) 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8257742B2 (en) * 2005-02-17 2012-09-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates for treating endometriosis
EP1865928A1 (en) * 2005-03-17 2007-12-19 Elan Pharma International Limited Nanoparticulate biphosphonate compositions
US20080181928A1 (en) * 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
US8802184B2 (en) 2007-05-30 2014-08-12 Abbott Cardiovascular Systems Inc. Medical devices containing biobeneficial particles
CA2702183A1 (en) * 2007-10-10 2009-04-16 Miv Therapeutics Inc. Lipid coatings for implantable medical devices
US20090148491A1 (en) * 2007-12-05 2009-06-11 Abbott Cardiovascular Systems Inc. Dual-Targeted Drug Carriers
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
CA2730085A1 (en) * 2008-07-09 2010-01-14 Board Of Regents Of The University Of Nebraska Functional micelles for hard tissue targeted delivery of chemicals
US20130315981A1 (en) * 2010-06-25 2013-11-28 The Trustees Of Columbia University In The City Of New York Method for inducing fat loss in mammals
GB201200868D0 (en) * 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
EP2769741A1 (en) * 2013-02-22 2014-08-27 Cardiatis S.A. Medical device with a biocompatible coating
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
WO2015175866A1 (en) 2014-05-16 2015-11-19 Biorest Ltd. Use of bisphosphonates as hiv/aids adjunctive treatment
CN109562352B (zh) 2016-08-01 2021-12-28 株式会社钟化 钙蛋白粒子的吸附材料以及吸附除去系统及其利用方法
CN106361701B (zh) * 2016-08-31 2019-08-27 上海交通大学 一种脂质体药物载体及其制备方法和应用
FR3068233A1 (fr) * 2017-07-03 2019-01-04 Omnium De Revalorisation Industrielle Odri Dispositif medical intra-arteriel et applications
JP6613290B2 (ja) 2017-11-28 2019-11-27 株式会社Ｓｕｂａｒｕ 運転アドバイス装置及び運転アドバイス方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
US4216211A (en) 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
WO1988000289A1 (en) 1986-07-09 1988-01-14 Engine Technology Limited Piston rings
CH675422A5 (es) * 1988-03-31 1990-09-28 Symphar Sa
US5196409A (en) 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
IL91362A0 (en) 1989-08-20 1990-03-19 Yissum Res Dev Co Bisphosphonates,process for preparing them and pharmaceutical compositions containing them
PH27186A (en) 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
CA2042159A1 (en) 1990-05-31 1991-12-01 Miguel A. Ondetti Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
AU678760B2 (en) * 1991-11-11 1997-06-12 Trustees Of The University Of Pennsylvania, The Methods of inhibiting restenosis
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FI92465C (fi) 1993-04-14 1994-11-25 Risto Tapani Lehtinen Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5652227A (en) 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5741514A (en) * 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
WO1997043437A2 (en) * 1996-05-15 1997-11-20 The University Of Sheffield Isopentenyl pyrophosphate isomerase (ipi) and/or prenyl transferase inhibitors
KR100192215B1 (ko) 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
AU729869B2 (en) * 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists
US5760030A (en) 1997-06-30 1998-06-02 Eli Lilly And Company Benzothiophene compounds and methods of use
US5932580A (en) 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
JP2002501757A (ja) * 1998-01-29 2002-01-22 メルク エンド カムパニー インコーポレーテッド ストレス応答性キナーゼのモジュレーターの特定方法
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
US5932563A (en) 1998-10-23 1999-08-03 Ohio State Research Foundation Methods for treating spinal cord injury
ATE238315T1 (de) 1998-12-10 2003-05-15 Aesgen Inc Verfahren zur herstellung von dinatriumpamidronat
WO2000064516A1 (en) 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates

Also Published As

Publication number Publication date
JP6088619B2 (ja) 2017-03-01
EP1094820B1 (en) 2004-03-24
AU758882B2 (en) 2003-04-03
SK472001A3 (en) 2001-09-11
WO2000003677A3 (en) 2000-05-04
DE69915834D1 (de) 2004-04-29
JP4663116B2 (ja) 2011-03-30
KR20010074711A (ko) 2001-08-09
NO20010224D0 (no) 2001-01-12
AU4646299A (en) 2000-02-07
JP2002520345A (ja) 2002-07-09
ATE471149T1 (de) 2010-07-15
JP2011037871A (ja) 2011-02-24
DE69915834T2 (de) 2005-03-24
IL125336A0 (en) 1999-03-12
BR9912066A (pt) 2001-04-10
EP1468691A1 (en) 2004-10-20
JP2013256524A (ja) 2013-12-26
CA2337175A1 (en) 2000-01-27
JP5498342B2 (ja) 2014-05-21
JP2016041724A (ja) 2016-03-31
CN1321090A (zh) 2001-11-07
US6719998B1 (en) 2004-04-13
EP1094820A2 (en) 2001-05-02
NO20010224L (no) 2001-03-09
ES2347553T3 (es) 2010-11-02
IL142172A0 (en) 2002-03-10
IL142172A (en) 2007-07-24
WO2000003677A2 (en) 2000-01-27
EP1468691B1 (en) 2010-06-16
EE200100025A (et) 2002-06-17
ATE262338T1 (de) 2004-04-15
CA2337175C (en) 2009-03-31
JP5903081B2 (ja) 2016-04-13
DE69942510D1 (de) 2010-07-29
PL345782A1 (en) 2002-01-02

Similar Documents

Publication Publication Date Title
EE200100025A (et) Restenoosi ravi
TW273515B (es)
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
NO980553L (no) Endotelinantagonist
DK0639577T3 (da) Phosphonooxymethyl- eller methylthiomethylestere af taxanderivater som antitumormidler
DE69840645D1 (en) Benzamidinderivate
IT1311922B1 (it) Composti farmaceutici.
TR200001906T2 (tr) Koks-Inhibitörleri olarak 2,3-ikameli indol bileşikleri.
PT971922E (pt) Compostos de tetra-hidropirido
AU6797298A (en) Halo-alkoxycarbonyl prodrugs
AR030537A1 (es) Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos
ITRM920734A0 (it) Composizioni per la stabilizzazione dei polimeri. (caso 153-5550)
DK1073447T3 (da) N1-modificerede glycopeptider
DK0605381T3 (da) Polymerforbindelse, især til medicinske anvendelser
ES2097181T3 (es) Composicion antidepresiva a base de nicotinamida-adenina-dinucleotido.
RU96117132A (ru) Антибактериальное средство - родиола розовая